Q-omics provides the consensus-scored CYB5RL profile across patient tissues and cancer cell-line models. CYB5RL expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, CYB5RL is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, CYB5RL RNA expression shows 20,672 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LIHC, THCA, and UVM as cancer lineages where CYB5RL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYB5RL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYB5RL survival associations across molecular data types. CYB5RL RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYB5RL RNA expression–survival associations across cancer types. High CYB5RL expression shows unfavorable associations in LIHC and LGG, but favorable associations in READ, KIRC, STAD and HNSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for CYB5RL RNA expression.
This table summarizes CYB5RL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CYB5RL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYB5RL shows lower tumor expression in THCA and higher tumor expression in LIHC, COAD, CHOL, STAD and BLCA. The THCA box plot shows higher CYB5RL RNA expression in normal versus tumor tissue (log2 FC = −0.604, t-test p < 0.001).
This table shows molecular features associated with CYB5RL in patient tissues and cancer cell lines. In patient samples, CYB5RL shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CYB5RL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
